ENTITY

Neurocrine Biosciences (NBIX US)

38
Analysis
Health CareUnited States
Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
more
bullishS&P 500 INDEX
22 Jul 2020 21:34

U.S. Equity Strategy: Bullish Outlook Intact

With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of...

Logo
392 Views
Share
bearishS&P 500 INDEX
20 May 2020 07:34

U.S. Equity Strategy: Round Trip Back To Resistance

Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...

Logo
216 Views
Share
bullishS&P 500 INDEX
28 Nov 2019 06:30

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Logo
379 Views
Share
bullishS&P 500 INDEX
20 Sep 2017 22:37

Vermilion Macro Vision - U.S. Equity Strategy: Sector Commentaries with Recommendations

Our last strategy “Fake Moves” highlighted our view that the markets were showing no parallel to the “fake news” narrative and indeed provided a...

Logo
430 Views
Share
bullishS&P 500 INDEX
06 Sep 2017 23:22

U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight

Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...

Logo
491 Views
Share
x